Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Trump administration is considering eliminating dozens of programs at HHS amid a mass reorganization of the agency.

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...